Search

Your search keyword '"Mangat, Pam K."' showing total 103 results
Start Over Author "Mangat, Pam K."
103 results on '"Mangat, Pam K."'

1. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Srkalovic, Gordan, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Ahn, Eugene R., additional, Brouse, Gregory, additional, Chan, John, additional, Mehmi, Inderjit, additional, Khalil, Maya, additional, Duvivier, Herbert L., additional, Gaba, Anu, additional, Leuva, Harshraj, additional, Thota, Ramya, additional, Yost, Kathleen J., additional, Grantham, Gina N., additional, Gregory, Abigail, additional, Hinshaw, Dominique C., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2024
Full Text
View/download PDF

2. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Cannon, Timothy L., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Chiu, Vi K., additional, Hwang, Jimmy, additional, Vijayvergia, Namrata, additional, Alese, Olatunji B., additional, Dib, Elie G., additional, Duvivier, Herbert L., additional, Klute, Kelsey A., additional, Sahai, Vaibhav, additional, Ahn, Eugene R., additional, Bedano, Pablo, additional, Behl, Deepti, additional, Sinclair, Sarah, additional, Thota, Ramya, additional, Urba, Walter J., additional, Yang, Eddy S., additional, Grantham, Gina N., additional, Hinshaw, Dominique C., additional, Gregory, Abigail, additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2024
Full Text
View/download PDF

3. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.

Author

Schuetze, Scott, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Meric-Bernstam, Funda, Calfa, Carmen J., Farrington, Laura Catherine, Livingston, Michael B., Wentzel, Kristopher, Behl, Deepti, Kier, Yelena, Marr, Alissa S., von Mehren, Margaret, Press, Joshua Z., Thota, Ramya, Grantham, Gina N., Gregory, Abigail, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.

Subjects
SARCOMA, CYCLIN-dependent kinases, CANCER patients, ALANINE aminotransferase, OVERALL survival
Abstract

PURPOSE: Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with soft tissue sarcoma with cyclin-dependent kinase 4 (CDK4) amplification treated with palbociclib are reported. METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0 to 2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration (SD16+) according to RECIST v1.1. The DC rate was estimated with a 90% CI. Secondary end points included OR, progression-free survival (PFS), overall survival (OS), duration of response, duration of SD, and safety. RESULTS: Forty-two patients with CDK4 amplification were enrolled. One patient was not evaluable for efficacy. One patient with partial response and 18 with SD16+ were observed for DC and OR rates of 46% (90% CI, 36 to 100) and 2% (95% CI, <1 to 13), respectively. Median PFS was 16 weeks (95% CI, 9 to 28) and median OS was 69 weeks (95% CI, 31 to 111) for evaluable patients. Twenty patients had at least one grade 3 to 4 adverse event (AE) at least possibly related to palbociclib, including alanine aminotransferase increase, anemia, fatigue, hypophosphatemia, leukopenia, neutropenia, and thrombocytopenia. No serious AEs were reported. CONCLUSION: Palbociclib met prespecified criteria to declare a signal of antitumor activity in patients with sarcoma and CDK4 amplification. Palbociclib met @ASCO #TAPUR criteria to declare antitumor activity in patients with CDK4-amplified liposarcoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Sahai, Vaibhav, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Suhag, Vijay, additional, Dib, Elie G., additional, Mehmi, Inderjit, additional, Kadakia, Kunal C., additional, Pisick, Evan, additional, Duvivier, Herbert L., additional, Le, Phat, additional, Li, Rui, additional, Michelin, David P., additional, Wilcox, Ryan E., additional, Grantham, Gina N., additional, Hinshaw, Dominique C., additional, Gregory, Abigail, additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2024
Full Text
View/download PDF

5. Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Ahn, Eugene R., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Calfa, Carmen J., additional, Alva, Ajjai S., additional, Suhag, Vijay, additional, Alese, Olatunji B., additional, Dotan, Efrat, additional, Hamid, Omid, additional, Yang, Eddy S., additional, Marr, Alissa S., additional, Palmer, Martin C., additional, Thompson, Forrest L., additional, Yost, Kathleen J., additional, Gregory, Abigail, additional, Grantham, Gina N., additional, Hinshaw, Dominique C., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2024
Full Text
View/download PDF

6. Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Al Baghdadi, Tareq, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Yost, Kathleen J, additional, Chiu, Vi Kien, additional, Duvivier, Herbert Leon, additional, McKean, Meredith, additional, Rueter, Jens, additional, Taylor, Mark A., additional, Grantham, Gina N., additional, Gregory, Abby, additional, Hinshaw, Dominique C., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2024
Full Text
View/download PDF

7. Talazoparib in Patients With Solid Tumors With BRCA1 / 2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.

Author

Srkalovic, Gordan, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R., Brouse, Gregory, Chan, John, Mehmi, Inderjit, Khalil, Maya, Duvivier, Herbert L., Gaba, Anu, Leuva, Harshraj, Thota, Ramya, Yost, Kathleen J., Grantham, Gina N., Gregory, Abigail, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.

Subjects
POLY(ADP-ribose) polymerase, EPIDERMAL growth factor receptors, CANCER patients, NON-small-cell lung carcinoma, BRCA genes, HORMONE receptor positive breast cancer, SKIN cancer
Abstract

PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with various solid tumors with germline or somatic BRCA1/2 mutations treated with talazoparib are reported. METHODS: Eligible patients had advanced solid tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Patients with germline BRCA -mutated human epidermal growth factor receptor 2–negative locally advanced or metastatic breast cancer were not eligible for this study. Primary end point was disease control (DC) determined by investigator assessment of objective response (OR) or stable disease (SD) of at least 16 weeks duration (SD16+). The results were evaluated on the basis of a one-sided exact binomial test with a null DC rate of 15% versus 35% (power = 0.82; α =.10). Secondary end points were OR, progression-free survival, overall survival, duration of response, duration of SD, and safety. RESULTS: Twenty-eight patients (20 cancer types) with BRCA1/2 mutations were enrolled from December 2019 to September 2021 and collapsed into a single histology pooled cohort for analysis. All patients were evaluable for efficacy. One complete response, nine partial response, and six SD16+ were observed for DC and OR rates of 57% (one-sided 90% CI, 43 to 100) and 36% (95% CI, 19 to 56), respectively. The null hypothesis of a 15% DC rate was rejected (P <.001). Patients with OR had the following tumor types: breast (2), nonmelanoma skin, mesothelioma, stomach, uterus, non–small cell lung cancer, ovary, hepatocellular carcinoma, and pancreas. Thirteen patients had at least one grade 3-5 adverse event (AE) or serious AE at least possibly related to talazoparib. All were consistent with the drug label except bilirubin increase and hyponatremia (both grade 3 AEs). CONCLUSION: Talazoparib demonstrated antitumor activity in patients with advanced solid tumors and BRCA1/2 mutations, including cancer types for which poly ADP-ribose polymerase inhibitors are not yet US Food and Drug Administration–approved. Talazoparib showed activity in patients with BRCA-mutated tumors for which PARP inhibitors are not yet FDA-approved. @ASCO #TAPUR [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Fisher, Julie G., Tait, David, Garrett-Mayer, Elizabeth, Halabi, Susan, Mangat, Pam K., Schink, Julian C., Alvarez, Ricardo H., Veljovich, Dan, Cannon, Timothy L., Crilley, Pamela A., Pollock, Theodore, Calfa, Carmen J., Al Baghdadi, Tareq, Thota, Ramya, Fleming, Nicole, Cotta, Jared A., Rygiel, Andrew L., Warren, Sasha L., and Schilsky, Richard L.

Published
2020
Full Text
View/download PDF

10. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Klute, Kelsey A., Rothe, Michael, Garrett-Mayer, Elizabeth, Mangat, Pam K., Nazemzadeh, Reza, Yost, Kathleen J., Duvivier, Herbert L., Ahn, Eugene R., Cannon, Timothy L., Alese, Olatunji B., Krauss, John C., Thota, Ramya, Calfa, Carmen J., Denlinger, Crystal S., OʼLone, Raegan, Halabi, Susan, Grantham, Gina N., and Schilsky, Richard L.

Published
2022
Full Text
View/download PDF

12. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Author

Calfa, Carmen J., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R., Burness, Monika L., Gogineni, Keerthi, Rohatgi, Nitin, Al Baghdadi, Tareq, Conlin, Alison, Gaba, Anu, Hamid, Omid, Krishnamurthy, Jairam, Gavini, Naga Jyothi, Gold, Philip J., Rodon, Jordi, Rueter, Jens, Thota, Ramya, Grantham, Gina N., and Hinshaw, Dominique C.

Subjects
SUNITINIB, CANCER patients, BREAST cancer, METASTATIC breast cancer, DRUG target
Abstract

PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results from cohorts of patients with metastatic breast cancer (BC) with FGFR1 and FGFR2 alterations treated with sunitinib are reported. METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16 weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Forty patients with BC with FGFR1 (N = 30; amplification only n = 26, mutation only n = 1, both n = 3) or FGFR2 (N = 10; amplification only n = 2, mutation only n = 6, both n = 2) alterations were enrolled. Three patients in the FGFR1 cohort were not evaluable for efficacy; all patients in the FGFR2 cohort were evaluable. For the FGFR1 cohort, two patients with partial response and four with SD16+ were observed for DC and OR rates of 27% (90% CI, 13 to 100) and 7% (95% CI, 1 to 24), respectively. The null hypothesis of 15% DC rate was not rejected (P =.169). No patients achieved DC in the FGFR2 cohort (P = 1.00). Thirteen of the 40 total patients across both cohorts had at least one grade 3-4 adverse event or serious adverse event at least possibly related to sunitinib. CONCLUSION: Sunitinib did not meet prespecified criteria to declare a signal of antitumor activity in patients with BC with either FGFR1 or FGFR2 alterations. Other treatments and clinical trials should be considered for these patient populations. Sunitinib did not demonstrate antitumor activity in patients with FGFR1-/2-amplified or -mutated breast cancer. @ASCO #TAPUR [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Yost, Kathleen J, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Duvivier, Herbert Leon, Ahn, Eugene R., Cannon, Timothy Lewis, Chiu, Vi Kien, Khalil, Maged F., Kim, Brian, Prinz, Allison Marie, Grantham, Gina N., Gregory, Abby, Hinshaw, Dominique C., Halabi, Susan, and Schilsky, Richard L.

Published
2024
Full Text
View/download PDF

14. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Duvivier, Herbert L., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Ahn, Eugene R., additional, Al Baghdadi, Tareq, additional, Alva, Ajjai S., additional, Dublis, Stephanie A., additional, Cannon, Timothy L., additional, Calfa, Carmen J., additional, Li, Rui, additional, Behl, Deepti, additional, Chiu, Vi K., additional, Gold, Philip J., additional, Marr, Alissa S., additional, Mileham, Kathryn F., additional, Powell, Steven Francis, additional, Rodon, Jordi, additional, Thota, Ramya, additional, Grantham, Gina N., additional, Gregory, Abigail, additional, Hinshaw, Dominique C., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

15. Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Srkalovic, Gordan, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Ahn, Eugene R, additional, Brouse, Gregory, additional, Chan, John K, additional, Mehmi, Inderjit, additional, Khalil, Maya, additional, Duvivier, Herbert Leon, additional, Gaba, Anu G., additional, Leuva, Harshraj, additional, Thota, Ramya, additional, Yost, Kathleen J, additional, Grantham, Gina N., additional, Gregory, Abigail, additional, Hinshaw, Dominique C., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

16. Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Mileham, Kathryn F., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Duvivier, Herbert L., additional, Calfa, Carmen J., additional, Dul, Carrie L., additional, Marr, Alissa S., additional, Ahn, Eugene R., additional, Behl, Deepti, additional, Hall, Michael J., additional, Mehmi, Inderjit, additional, Gaba, Anu, additional, Leidner, Rom, additional, Zalupski, Mark M., additional, Grantham, Gina N., additional, Gregory, Abigail, additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

17. Abstract CT231: Temsirolimus (T) in patients (pts) with solid tumors with PTEN mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Wentzel, Kristopher, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Ding, Li, additional, Pisick, Evan, additional, Krishnan, Mridula, additional, Behl, Deepti, additional, Alese, Olatunji B., additional, Calfa, Carmen J., additional, Cooper, Kathrine A., additional, Duvivier, Herbert L., additional, Induru, Raghava Reddy, additional, Ruzich, Janet C., additional, Zhao, Song, additional, Grantham, Gina N., additional, Gregory, Abigail, additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

18. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study

Author

Ahn, Eugene R., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Ali-Ahmad, Hussein M., additional, Chan, John, additional, Maitland, Michael L., additional, Patel, Sapna R., additional, Reese, Zachary, additional, Balmanoukian, Ani S., additional, Drescher, Charles W., additional, Li, Rui, additional, Tsimberidou, Apostolia M., additional, Leath, Charles A., additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

19. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Author

Meric-Bernstam, Funda, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Gutierrez, Rodolfo, Ahn, Eugene R., Cannon, Timothy L., Powell, Steven, Krauss, John C., Reynolds, Christopher M., von Mehren, Margaret, Behl, Deepti, Calfa, Carmen J., Duvivier, Herbert L., Kaplan, Henry G., Livingston, Michael B., Sharma, Manish R., Urba, Walter J., Grantham, Gina N., and Hinshaw, Dominique C.

Subjects
VEMURAFENIB, BRAF genes, CANCER patients, PATIENT experience, ANTINEOPLASTIC agents, OVARIAN cancer
Abstract

PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. The results in a cohort of patients with solid tumors with BRAF mutations treated with cobimetinib plus vemurafenib are reported. METHODS: Eligible patients had measurable disease (RECIST v.1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as complete response (CR) or partial response (PR) or stable disease of at least 16-weeks duration (SD16+). Low-accruing histology-specific cohorts with BRAF mutations treated with cobimetinib plus vemurafenib were collapsed into a single histology-pooled cohort for this analysis. The results were evaluated on the basis of a one-sided exact binomial test with a null DC rate of 15% versus 35% (power,.82; α,.10). The secondary end points were objective response (OR), progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Thirty-one patients with solid tumors with BRAF mutations were enrolled. Twenty-eight patients were evaluable for efficacy. Patients had tumors with BRAF V600E (n = 26), K601E (n = 2), or other (n = 3) mutations. Two patients with CR (breast and ovarian cancers; V600E), 14 with PR (13 V600E, one N581I), and three with SD16+ (two V600E, one T599_V600insT) were observed with a DC rate of 68% (P <.0001; one-sided 90% CI, 54 to 100) and an OR rate of 57% (95% CI, 37 to 76). Nineteen patients experienced ≥one drug-related grade 3-5 adverse event or serious adverse event including one death attributed to treatment-related kidney injury. CONCLUSION: Cobimetinib plus vemurafenib showed antitumor activity in patients with advanced solid tumors with BRAF V600E mutations; additional study is warranted to confirm the antitumor activity in tumors with non-V600E BRAF mutations. @ASCO #TAPUR results build upon efficacy of BRAF + MEK inhibitors in patients with advanced solid tumors and BRAF V600E mutations [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial.

Author

Mangat, Pam K, Garrett-Mayer, Elizabeth, Perez, Jacqueline K, and Schilsky, Richard L

Subjects
THERAPEUTIC use of antineoplastic agents, SPECIALTY hospitals, CLINICAL trials, COMMUNITY health services, GENETIC testing, INDIVIDUALIZED medicine, EVIDENCE-based medicine, CANCER treatment, CONCEPTUAL structures, COMPARATIVE studies, DESCRIPTIVE statistics, RESEARCH funding, TUMORS, OFF-label use (Drugs)
Abstract

The conceptual framework of pragmatism in clinical trials is explored using the American Society of Clinical Oncology's pragmatic, non-randomized, phase II, multi-center basket clinical trial, the Targeted Agent and Profiling Utilization Registry Study (NCT02693535) as a model. The Targeted Agent and Profiling Utilization Registry Study aims to identify signals of drug activity when Food and Drug Administration approved drugs are matched to pre-specified genomic targets in patients with advanced cancer outside of their approved indication(s). The objectives of the study are to generate evidence of potential signals of activity in targeted therapies prescribed in an off-label setting as well as to expose and educate community cancer centers to genomic testing and precision medicine through the study protocol. The principles of pragmatic trial design can be applied across a broad spectrum of evidence-generation strategies, from explanatory trials to real-world evidence studies, and are briefly discussed. American Society of Clinical Oncology's Targeted Agent and Profiling Utilization Registry Study falls closer to the pragmatic end of this spectrum as it seeks to assess the efficacy of Food and Drug Administration approved drugs used outside their approved indications under usual care conditions, yielding results generalizable to the population that would likely receive the intervention in practice, while still adhering to rigorous data quality standards. The Targeted Agent and Profiling Utilization Registry Study's pragmatic objectives, characteristics, strengths, and limitations in its implementation are discussed and demonstrate that a large, multi-center, precision medicine basket trial can be mounted in the context of community practice and can generate clinically useful information with minimal burden to patients and clinical trial sites. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Rohatgi, Nitin, Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Meric-Bernstam, Funda, Pisick, Evan, Alese, Olatunji B., Reynolds, Christopher M., Thota, Ramya, Vaccaro, Gina M., von Mehren, Margaret, Arend, Rebecca C., Chiu, Vi K., Duvivier, Herbert L., Gold, Philip J., Hack, Keely, Marr, Alissa S., Winer, Arthur, Grantham, Gina N., and Hinshaw, Dominique C.

Subjects
NIVOLUMAB, IPILIMUMAB, CANCER patients, AUTOMATED teller machines, DRUG target
Abstract

PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. Results of a cohort of patients with solid tumors with ATM mutations treated with nivolumab plus ipilimumab are reported. METHODS: Eligible patients had measurable disease (RECIST v.1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Primary end point was disease control (DC), defined as complete (CR) or partial (PR) response or stable disease (SD) of at least 16 weeks duration (SD16+). Low-accruing histology-specific cohorts with ATM mutations treated with nivolumab plus ipilimumab were collapsed into a single histology-pooled cohort for this analysis. The results were evaluated based on a one-sided exact binomial test with a null DC rate of 15% versus 35% (power =.84; α =.10). Secondary end points were objective response (OR), progression-free survival, overall survival, duration of response, duration of SD, and safety. RESULTS: Twenty-nine patients with 10 tumor types with ATM mutations were enrolled from January 2018 to May 2020. One patient was not evaluable for efficacy. One CR, three PR, and three SD16+ were observed for DC and OR rates of 24% (P =.13; one-sided 90% CI: 14 to 100) and 14% (95% CI: 4 to 32), respectively. The null hypothesis of 15% DC rate was not rejected. Eleven patients had one treatment-related grade 3 adverse event (AE) or serious AE. There were two treatment-related patient deaths including immune-related encephalitis and respiratory failure. CONCLUSION: Nivolumab plus ipilimumab did not meet prespecified criteria to declare a signal of activity in patients with solid tumors with ATM mutations. Nivolumab + ipilimumab did not meet @ASCO #TAPUR criteria to declare antitumor activity in patients w/ ATM-mutated solid tumors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Behl, Deepti, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Farrington, Laura Catherine, additional, Crysler, Oxana V., additional, Dib, Elie G., additional, Duvivier, Herbert Leon, additional, Hall, Michael J., additional, Salmon, John Stuart, additional, Alese, Olatunji B., additional, Marr, Alissa S., additional, Ngirailemesang, Isa, additional, Polavaram, Latha, additional, Thota, Ramya, additional, Yang, Eddy Shih-Hsin, additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

23. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study

Author

Yang, Eddy S., primary, Halabi, Susan, additional, Rothe, Michael, additional, Garrett-Mayer, Elizabeth, additional, Mangat, Pam K., additional, Pisick, Evan, additional, Dib, Elie, additional, Burgess, Earle F., additional, Zakem, Michael, additional, Rohatgi, Nitin, additional, Bilen, Mehmet A., additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

24. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.

Author

Ganti, Apar K., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Dib, Elie G., Duvivier, Herbert L., Ahn, Eugene R., Behl, Deepti, Borghaei, Hossein, Balmanoukian, Ani S., Gaba, Anu, Li, Rui, Osei-Boateng, Kwabena, Thota, Ramya, Grantham, Gina N., Gregory, Abigail, Halabi, Susan, and Schilsky, Richard L.

Subjects
CANCER patients, LUNG cancer, TRASTUZUMAB, INSERTION mutation, NON-small-cell lung carcinoma
Abstract

PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from a cohort of patients with lung cancer and ERBB2 mutation or amplification treated with pertuzumab plus trastuzumab (P + T) are reported. METHODS: Eligible patients had advanced lung cancer of any histology, no standard treatment options, measurable disease (RECIST v1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and tumors with ERBB2 mutation or amplification. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) per RECIST v. 1.1 or stable disease (SD) of at least 16 weeks duration (SD16+). Secondary end points included safety, duration of response, duration of SD, progression-free survival, and overall survival. RESULTS: Twenty-eight patients with lung cancer (27 non–small-cell, 1 small-cell) and ERBB2 mutation (n = 15), ERBB2 amplification (n = 12), or both (n = 1) were enrolled from November 2016 to July 2020. All patients were evaluable for efficacy and toxicity. Three patients with partial response (two ERBB2 mutation; one both mutation and amplification) and seven patients with SD16+ (five ERBB2 mutation; two amplification) were observed for a DC rate of 37% (95% CI, 21 to 50; P =.005) and OR rate of 11% (95% CI, 2 to 28). Five patients had one or more grade 3 or 4 adverse or serious adverse events at least possibly related to P + T. CONCLUSION: Combination P + T showed evidence of antitumor activity in heavily pretreated patients with non–small-cell lung cancer and ERBB2 mutation or amplification, particularly those with ERBB2 exon 20 insertion mutations. Pertuzumab + trastuzumab had antitumor activity in pretreated patients with ERBB2-mutated NSCLC @ASCO #TAPUR. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Abstract CT110: Olaparib (O) in patients (pts) with solid tumors with ATM mutation or deletion: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Mileham, Kathryn F., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Yang, Eddy S., additional, Alese, Olatunji B., additional, Jain, Angela, additional, Duvivier, Herbert L., additional, Palmbos, Phillip, additional, Ahn, Eugene R., additional, Aragon-Ching, Jeanny B., additional, Beekman, Kathleen W., additional, Behl, Deepti, additional, Meric-Bernstam, Funda, additional, Gutierrez, Rodolfo, additional, Sanford, Amy, additional, Thota, Ramya, additional, Zakem, Michael, additional, Zhao, Song, additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

26. Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Srkalovic, Gordan, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Nazemzadeh, Reza, additional, Cannon, Timothy Lewis, additional, Duvivier, Herbert Leon, additional, Yost, Kathleen J, additional, Pakkala, Suchita, additional, Alva, Ajjai Shivaram, additional, Behl, Deepti, additional, Gold, Philip Jordan, additional, Calfa, Carmen Julia, additional, Ngirailemesang, Melissa, additional, Powell, Steven Francis, additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

27. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1 / 2 Mutation: Results From the TAPUR Study.

Author

Yang, Eddy S., Halabi, Susan, Rothe, Michael, Garrett-Mayer, Elizabeth, Mangat, Pam K., Pisick, Evan, Dib, Elie, Burgess, Earle F., Zakem, Michael, Rohatgi, Nitin, Bilen, Mehmet A., O'Lone, Raegan, Grantham, Gina N., and Schilsky, Richard L.

Subjects
PROSTATE cancer patients, PROSTATE cancer, BRCA genes, OLAPARIB, CANCER patients, PROGRESSION-free survival
Abstract

PURPOSE: The TAPUR Study is a phase II basket trial that aims to evaluate activity of approved targeted agents in patients with advanced cancers with potentially actionable genomic variants. Data from a cohort of patients with metastatic castrate-resistant prostate cancer (mCRPC) and BRCA1 / 2 mutations treated with olaparib are reported. METHODS: Eligible patients with measurable mCRPC were matched to treatment according to protocol-specified genomic matching rules. Patients had no remaining standard treatment options, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Simon's two-stage design was used with a primary end point of disease control, defined as objective response or stable disease of at least 16-week duration. Secondary end points include radiographic progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Thirty patients with mCRPC with BRCA1 / 2 mutations were treated with olaparib. The disease control rate was 69% (95% CI, 51 to 81), and the objective response rate was 58% (95% CI, 37 to 77). The median radiographic progression-free survival and the median overall survival were 38.4 (95% CI, 16.3 to 52.1) weeks and 76.4 (95% CI, 49.3 to 106.0) weeks, respectively. Six of 30 (20%) patients experienced grade 3-4 adverse or serious adverse events including anemia, aspiration, decreased WBC count, and fatigue. CONCLUSION: Olaparib has antitumor activity in patients with mCRPC with BRCA1 / 2 mutations and warrants further study to determine how to best integrate it into the standard treatment of patients with BRCA1 / 2 -mutated prostate cancer. Olaparib showed a positive signal of activity in real-world patients w/prostate cancer w/BRCA1 or BRCA2 mutations @ASCO #TAPUR. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Vaccaro, Gina M., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Hwang, Jimmy J., additional, Alese, Olatunji B., additional, Khalil, Maged F., additional, Hameed, Muhammad Khurram, additional, Duvivier, Herbert Leon, additional, Cannon, Timothy Lewis, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

29. Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Grem, Jean L., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Khalil, Maged F., additional, Rogosin, Shane O., additional, Salmon, John Stuart, additional, Cannon, Timothy Lewis, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

30. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Alva, Ajjai S., primary, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Hansra, Damien, additional, Calfa, Carmen J., additional, Khalil, Maged F., additional, Ahn, Eugene R., additional, Cannon, Timothy L., additional, Crilley, Pamela, additional, Fisher, Julie G., additional, Haslem, Derrick S., additional, Shrestha, Sagun, additional, Antonelli, Kaitlyn R., additional, Butler, Nicole L., additional, Warren, Sasha L., additional, Rygiel, Andrew L., additional, Ranasinghe, Shamika, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2021
Full Text
View/download PDF

31. Abstract CT173: Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) withFGFR1mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Calfa, Carmen, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Ahn, Eugene, additional, Gogineni, Keerthi, additional, Rohatgi, Nitin, additional, Burness, Monika L., additional, Gaba, Anu, additional, Hamid, Omid, additional, Albaghdadi, Tareq, additional, Conlin, Alison, additional, Gold, Philip, additional, Rodon, Jordi, additional, Thota, Ramya, additional, and Schilsky, Richard L., additional

Published
2021
Full Text
View/download PDF

32. Comparing phase 3 “go” decisions (Ph3-GO) between single arm trials with real-world external control (SAT+rwEC) versus randomized phase 2 trials (rPh2).

Author

Hobbs, Brian, primary, Ton, Thanh, additional, Li, Xiao, additional, Hong, David S., additional, Hubbard, Rebecca A., additional, Mangat, Pam K., additional, Capra, William, additional, Kong, Shengchun, additional, Pang, Herbert, additional, Samant, Meghna, additional, Segal, Brian D., additional, and Garrett-Mayer, Liz, additional

Published
2021
Full Text
View/download PDF

33. Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Ali-Ahmad, Hussein Moustapha, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Liz, additional, Ahn, Eugene, additional, Chan, John, additional, Maitland, Michael L., additional, Balmanoukian, Ani Sarkis, additional, Patel, Sapna R., additional, Reese, Zachary, additional, Drescher, Charles W., additional, Leath, Charles A., additional, Li, Rui, additional, Tsimberidou, Apostolia Maria, additional, and Schilsky, Richard L., additional

Published
2021
Full Text
View/download PDF

34. Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Schuetze, Scott, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Liz, additional, Meric-Bernstam, Funda, additional, Farrington, Laura Catherine, additional, Calfa, Carmen, additional, D'Andre, Stacy D., additional, Livingston, Michael B., additional, Thota, Ramya, additional, Marr, Alissa S., additional, von Mehren, Margaret, additional, Wentzel, Kristopher, additional, and Schilsky, Richard L., additional

Published
2021
Full Text
View/download PDF

35. Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Pisick, Evan P., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Liz, additional, Worden, Francis P., additional, Bauman, Jessica R., additional, Fu, Siqing, additional, Leidner, Rom S., additional, Balmanoukian, Ani Sarkis, additional, Calfa, Carmen, additional, Carrizosa, Daniel R., additional, D'Andre, Stacy D., additional, Nabell, Lisle, additional, Park, Min S., additional, Powell, Steven Francis, additional, Thota, Ramya, additional, and Schilsky, Richard L., additional

Published
2021
Full Text
View/download PDF

36. Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Ahn, Eugene R., primary, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Dib, Elie G., additional, Haggstrom, Daniel E., additional, Alguire, Kathryn B., additional, Calfa, Carmen J., additional, Cannon, Timothy L., additional, Crilley, Pamela A., additional, Gaba, Anu G., additional, Marr, Alissa S., additional, Sangal, Ashish, additional, Thota, Ramya, additional, Antonelli, Kaitlyn R., additional, Islam, Samiha, additional, Rygiel, Andrew L., additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2020
Full Text
View/download PDF

37. Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Pisick, Evan P., primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, Yang, Eddy Shih-Hsin, additional, Dib, Elie G., additional, Burgess, Earle Frederick, additional, Zakem, Michael Howard, additional, Rohatgi, Nitin, additional, Bilen, Mehmet Asim, additional, Warren, Sasha L., additional, Anderson, Sarah T., additional, Rygiel, Andrew Lawrence, additional, and Schilsky, Richard L., additional

Published
2020
Full Text
View/download PDF

38. Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Ahn, Eugene R, primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, Calfa, Carmen Julia, additional, Alva, Ajjai Shivaram, additional, Suhag, Vijay S., additional, Hamid, Omid, additional, Dotan, Efrat, additional, Yang, Eddy Shih-Hsin, additional, Alese, Olatunji B., additional, Yost, Kathleen J, additional, Marr, Alissa S., additional, Palmer, Martin Clive, additional, Thompson, Forrest L., additional, Rygiel, Andrew Lawrence, additional, Anderson, Sarah T., additional, Islam, Samiha, additional, and Schilsky, Richard L., additional

Published
2020
Full Text
View/download PDF

39. Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.

Author

Gupta, Ranju, primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, D'Andre, Stacy D., additional, Meiri, Eyal, additional, Shrestha, Sagun, additional, Warren, Sasha L., additional, Ranasinghe, Shamika, additional, and Schilsky, Richard L., additional

Published
2020
Full Text
View/download PDF

40. Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Meiri, Eyal, primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, Shrestha, Sagun, additional, Ahn, Eugene R., additional, Osayameh, Olufunlayo, additional, Perla, Venu, additional, and Schilsky, Richard L., additional

Published
2020
Full Text
View/download PDF

42. Palbociclib in Patients With Pancreatic and Biliary Cancer WithCDKN2AAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Al Baghdadi, Tareq, primary, Halabi, Susan, additional, Garrett-Mayer, Elizabeth, additional, Mangat, Pam K., additional, Ahn, Eugene R., additional, Sahai, Vaibhav, additional, Alvarez, Ricardo H., additional, Kim, Edward S., additional, Yost, Kathleen J., additional, Rygiel, Andrew Lawrence, additional, Antonelli, Kaitlyn R., additional, Butler, Nicole L., additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

43. Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) with FLT-3 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Alvarez, Ricardo H., primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, Baghdadi, Tareq Al, additional, Ahn, Eugene R., additional, Chai, Seungjean, additional, Rygiel, Andrew L., additional, Antonelli, Kaitlyn R., additional, Islam, Samiha, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

44. Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reported KRAS, NRAS, BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Fisher, Julie, primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, Alvarez, Ricardo H., additional, Cannon, Timothy L., additional, Crilley, Pamela, additional, Pollock, Theodore, additional, Baghdadi, Tareq Al, additional, Cotta, Jared A., additional, Rygiel, Andrew L., additional, Antonelli, Kaitlyn R., additional, Islam, Samiha, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

45. Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reportedKRAS, NRAS, BRAFmutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Fisher, Julie, primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, Alvarez, Ricardo H., additional, Cannon, Timothy L., additional, Crilley, Pamela, additional, Pollock, Theodore, additional, Baghdadi, Tareq Al, additional, Cotta, Jared A., additional, Rygiel, Andrew L., additional, Antonelli, Kaitlyn R., additional, Islam, Samiha, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

46. Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) withFLT-3alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Alvarez, Ricardo H., primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, Baghdadi, Tareq Al, additional, Ahn, Eugene R., additional, Chai, Seungjean, additional, Rygiel, Andrew L., additional, Antonelli, Kaitlyn R., additional, Islam, Samiha, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

48. Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Alva, Ajjai Shivaram, primary, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Alvarez, Ricardo H., additional, Calfa, Carmen Julia, additional, Khalil, Maged F., additional, Ahn, Eugene R, additional, Cannon, Timothy Lewis, additional, Crilley, Pamela A., additional, Fisher, Julie Gottlieb, additional, Haslem, Derrick S., additional, Shrestha, Sagun, additional, Antonelli, Kaitlyn R., additional, Butler, Nicole L., additional, Warren, Sasha L., additional, Rygiel, Andrew Lawrence, additional, Ranasinghe, Shamika, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

49. Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Ahn, Eugene R, primary, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Dib, Elie G., additional, Haggstrom, Daniel Ernest, additional, Alguire, Kathryn B., additional, Alvarez, Ricardo H., additional, Calfa, Carmen Julia, additional, Cannon, Timothy Lewis, additional, Crilley, Pamela A., additional, Gaba, Anu G., additional, Marr, Alissa S., additional, Sangal, Ashish, additional, Thota, Ramya, additional, Antonelli, Kaitlyn R., additional, Islam, Samiha, additional, Rygiel, Andrew Lawrence, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

50. Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study

Author

Mangat, Pam K., primary, Halabi, Susan, additional, Bruinooge, Suanna S., additional, Garrett-Mayer, Elizabeth, additional, Alva, Ajjai, additional, Janeway, Katherine A., additional, Stella, Philip J., additional, Voest, Emile, additional, Yost, Kathleen J., additional, Perlmutter, Jane, additional, Pinto, Navin, additional, Kim, Edward S., additional, and Schilsky, Richard L., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results